Edgar Filing: ANTIGENICS INC /DE/ - Form 4

ANTIGENI	CS INC /DE/										
Form 4											
March 14, 2									0145.4		
FORM	14 UNITED	STATES	SECU	DITIES /	ND FY	СПАМ	ICE	COMMISSION	т	PPROVAL	
Check t	UNITED	SIAIES		shington			GE		NUMB	3235-0287	
if no lor	nger				DENIER				Expires:	January 31, 2005	
subject Section	16.	CHA	NGES IN SECUI		ICIAL	VNERSHIP OF	Estimated burden hou	average Jrs per			
Form 4 or Form 5 obligations may continue.responseSee Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										. 0.5	
(Print or Type	Responses)										
1. Name and ARMEN G	2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer					
		A. 1.11 \	ANTIGENICS INC /DE/ [AGEN]					(Check all applicable)			
(Mo				. Date of Earliest Transaction Month/Day/Year))3/10/2005				X Director 10% Owner X Officer (give title Other (specify below) below) Chairman and CEO			
				nendment, Date Original Ionth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
NEW YOR	RK, NY 10111								More than One R		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securit	ies A	cquired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D)		Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount		Price	(Instr. 3 and 4)			
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	•		•				
					inforr	nation o	conta	pond to the collect ained in this form and unless the for	are not	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

displays a currently valid OMB control number.

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securitie
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed o (Instr. 3, 4, 5)	f(D)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Option (right to buy)	\$ 6.92	03/10/2005		A		300,000		03/10/2006(1)	03/10/2015	Common Stock	300,0

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
ARMEN GARO H 630 FIFTH AVENUE SUITE 918 NEW YORK, NY 10111	X		Chairman and CEO					
Signatures								
Christine M. Klaskin, by Power Attorney	r of	03/	/14/2005					
**Signature of Reporting Person			Date					

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v). *

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options vest in four equal annual installments beginning March 10, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.